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Abstract
The invasive phenotype of glioblastoma multiforme
(GBM) is a hallmark of malignant process, yet molec-
ular mechanisms that dictate this locally invasive
behavior remain poorly understood. Gene expression
profiles of human glioma cells were assessed from
laser capture–microdissected GBM cells collected
from paired patient tumor cores and white matter–
invading cell populations. Changes in gene expression
in invading GBM cells were validated by quantitative
reverse transcription polymerase chain reaction (QRT-
PCR) and immunohistochemistry in an independent
sample set. QRT-PCR confirmed the differential ex-
pression in 19 of 21 genes tested. Immunohistochem-
ical analyses of autotaxin (ATX), ephrin B3, B-cell
lymphoma-w (BCLW), and protein tyrosine kinase 2
beta showed them to be expressed in invasive glioma
cells. The known GBM markers, insulin-like growth
factor binding protein 2 and vimentin, were robustly
expressed in the tumor core. A glioma invasion tissue
microarray confirmed the expression of ATX and
BCLW in invasive cells of tumors of various grades.
GBM phenotypic and genotypic heterogeneity is well
documented. In this study, we show an additional layer
of complexity: transcriptional differences between
cells of tumor core and invasive cells located in the
brain parenchyma. Gene products supporting invasion
may be novel targets for manipu
lation of brain tumor behavior with consequences on
treatment outcome.
Neoplasia (2005) 7, 7–16
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Introduction
Glioblastoma multiforme (GBM) is the most common and
most lethal primary malignant brain tumor. These nonmeta-
static tumors are highly locally invasive [1], diffusely dis-
seminating into the brain and placing cells outside the
margin of therapeutic resection. Current therapies address
the bulk of the tumor mass, whereas recurrence is most often
within 3 cm of the resection margin [2] and accounts for the fatal
outcome of the disease. The infiltrative path of GBM into the
normal brain is not random; it often follows white matter tracts
and extends along perivascular spaces, the glia limitans
externa and the subependyma [3]. Little is known about the
distinct biology of invasive glioblastoma cells in situ, but their
diffuse infiltration suggests the activation of genetic and cellular
programs that distinguish them from cells in the tumor core.
Microarray technology has proven to be very useful in the
molecular classification of astrocytic tumor grades [4–9], gen-
erating evidence of a molecular evolution driving progressive
stages of astrocytoma malignancy. Gene expression analysis
enhances histopathologic diagnosis [7,8], specifically of non-
classic tumor histologies, providing a more accurate prognosis
[4,10]. It is hoped that molecular characterization of tumor
subtypes will lead to the application of therapy customized to
a particular tumor’s biology. This report illustrates the usage of
cDNA microarrays to discern differential gene expression
comparing glioma cells at a stationary, proliferative site within
the tumor core to cells invading the surrounding brain exhibiting
a diffuse, motile behavior. Patterns of gene expression by cells
at the tumor core, such as the presence of insulin-like growth
factor binding protein 2 (IGFBP2 ), were consistent with pub-
lished cDNA microarray characterizations of GBM [5,6,9].
Genes upregulated in invasive cells depict a commitment to
motility and invasion, such as the autocrine motility factor,
autotaxin (ATX ), and protein tyrosine kinase 2 beta (PYK2 ).
Increased expression of the antiapoptotic BCLW and death-
associated protein 3 (DAP3 ), a protein previously found to be
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transcriptionally upregulated in invasive glioma [11], points to
potential interrelationships between motility and apoptosis
resistance.
We propose that there is an invasion-specific gene
expression profile—one that enables GBM cells to move
through the brain parenchyma, creating two distinct subpo-
pulations: the stationary, proliferative tumor core and the
motile, invading tumor rim cells. Their distinct gene expres-
sion profiles suggest novel therapeutic targets that address
dispersed, infiltrating tumor cells. This introduces the possi-
bility of multiagent treatment modalities, specifically targeting
invasive cells in conjunction with classic treatments aimed at
the proliferating tumor core cells.
Materials and Methods
Clinical Samples and Histology
Human glioblastoma tumor samples were obtained from
patients who underwent primary therapeutic subtotal or total
tumor resection performed under image guidance. All speci-
mens (13 in number) were collected and submitted to the
study under institutional review board–approved protocols.
None of the patients had been subjected to chemotherapy or
radiotherapy prior to resection. The samples, which were
obtained from the main tumor mass and the invasive edge,
were immediately frozen on dry ice to be used in laser
Table 1. Genes Downregulated in Invasive GBM.
I/C Accession Number Number Description
Extracellular
0.16 N91385 MS4A1 Membrane-spanning
4-domains, A1
0.2 AA429895 ABCC3 ATP-binding cassette C
(CFTR/MRP)
0.25 AA448569 SRPX Sushi repeat –containing protein,
X chromosome
0.25 AA598653 OSF2 Osteoblast-specific factor 2
(fasciclin 1– like)
0.33 N76878 DEPP Decidual protein induced by
progesterone
0.33 T77595 TNC Tenascin C (hexabrachion)
0.33 H79047 IGFBP2 Insulin-like growth factor binding
protein 2
0.33 R7563.5 COLA1 Collagen, type V, alpha 1
0.33 T49159 SERPIN Serine (or cysteine) proteinase
inhibitor, clade B 2
0.5 R71440 SERPINH2 Serine (or cysteine) proteinase
inhibitor, clade H2 (hsp47)
0.5 M65062 IGFBP5 Insulin-like growth factor
binding protein 5
Vascular involvement/angiogenesis
0.25 AA029842 MTCP1 Mature T-cell proliferation 1
0.25 AA401693 CD163 CD163
0.33 H16637 VCAM1 Vascular cell adhesion
molecule 1
0.33 AA421296 CD68 CD68 antigen
0.33 A4491191 IF116 Interferon gamma– inducible
protein 16
0.5 R19956 VEGF Vascular endothelial growth
factor
Signal transduction
0.09 W05628 PSHL Phosphoserine phosphatase– like
0.09 W07300 AP1G1 Adaptor-related protein
complex 1, gamma 1
0.25 N63635 P1M1 Pim-1 protooncogene gene
0.25 AA598496 IQGAP IQ motif containing
GTPase-activating protein 1
0.25 AA019996 PTGER4 Prostaglandin E receptor 4
(subtype EP4)
0.25 AA397813 CKS2 CDC28 protein kinase regulatory
subunit 2
0.25 AA446290 ST5 Suppression of tumorigenicity 5
0.25 AA489246 ST14 Suppression of tumorigenicity 14
0.25 N53172 RDCl G protein–coupled receptor
0.33 AA443506 ARHGAP1 Rho GTPase–activating
protein 1
0.33 H62028 DYRK3 Dual-specificity tyrosine (Y)
phosphorylation-regulated
kinase 3
0.33 AA453774 RGS16 Regulator of G-protein
signalling 16
0.33 AA487560 CAV1 Caveolin 1, caveolae protein,
22 kDa
0.33 AA478542 AKAP12 AKAP12 A kinase (PRKA)
anchor protein (gravin) 12
0.5 AA029737 TK2 Thymidine kinase 2, mitochondrial
0.5 AA496785 ABL1 Abelson murine leukemia viral
oncogene homolog 1
Cytoskeleton
0.09 AA521431 PFN1 Profilin 1
0.2 R22977 MSN Moesin
0.25 AA490267 PLEK Plekstrin
0.33 AA486942 CAPG Capping protein (actin filament),
gelsolin-like
0.33 AA411440 VIL2 Villin (ezrin)
0.4 AA069414 GFAP Glial fibrillary acidic protein
0.5 AA487812 VIM Vimentin
Table 1. (continued)
Apoptosis
0.33 AA668595 PIG3 p53-induced gene 3
0.33 AA228130 PSIP2 PC4- and SFRSI-interacting
protein 2
0.37 H45000 CASP4 Caspase 4
Transcription
0.08 AA280677 ZNF258 Zinc finger protein 258
0.33 AA402207 EYA2 Eyes absent (Drosophila) homolog 2
0.33 N94468 JUNB Jun B protooncogene
0.33 H26183 CEBPB CCAAT/enhancer–binding protein
(C/EBP), beta
0.5 P18146 EGR1 Early growth response 1
Proliferation
0.33 AA454572 MCM2 MCM2 minichromosome
maintenance–deficient 2, mitotin
Unknown function
0.045 H93118 H93118 Hypothetical protein FLJ12592
0.04 R76499 R76499 Hypothetical protein BCOO7384
0.11 N29376 MNDA Myeloid cell nuclear
differentiation antigen
0.12 R78516 SELT Selenoprotein T
0.14 AA481758 DNAJBl DnaJ (Hsp40) homolog,
subfamily B, member 1
0.2 AA490991 HNRPF Heterogeneous nuclear
ribonucleoprotein F
0.2 N8Ol29 MTIL Metallothionein 1L
0.2 R64251 DDX38 DEAD/H (Asp-Glu-Ala-Asp/His)
box polypeptide 38
0.25 AA486518 CLIC1 Chloride intracellular channel 1
0.33 N49629 UBD Ubiquitin D
0.33 AA459318 TPD52 TPD52 tumor protein D52
I/C = average cDNA microarray ratios of invasive cells over tumor core cells.
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capture microdissection (LCM). Another portion was fixed in
paraformaldehyde and paraffin-embedded for histologic
evaluation. Histologic diagnosis was made by standard light
microscopic evaluation of hematoxylin and eosin–stained
sections. All tumor samples were classified as WHO grade
IV GBM [12].
LCM
LCM was performed as described previously [13]. Briefly,
1000 to 2000 tumor core and invasive cells were dissected
from 8-mm sections cut from four flash-frozen glioblastoma
(WHO grade IV) tumors. Cells in the tumor core were
identified and captured; tumor cells immediately adjacent
to necrotic areas; cortical areas; cells with small, regular
nuclei; and endothelial and blood cells were avoided. White
matter– invading GBM cells were identified by means of their
nuclear atypia and heteropyknotic staining, which was con-
sistent with that of the cells within the tumor core. Reactive
astrocytes were discriminated through their distinct stellate
morphology with eosinophilic cytoplasm and large, acentric,
round nuclei, and were avoided.
RNA Isolation and Amplification
Total RNA was isolated from 1000 to 2000 LCM cells
using the PicoPure RNA Isolation Kit (Arcturus, Mountain
View, CA), and quantified by real-time reverse transcription
polymerase chain reaction (RT-PCR) performed with the
LightCycler (Roche, Mannheim, Germany). This consisted
of performing PCR with Histone 3B primers using a serial
dilution of cDNA of known concentration as a standard. The
remaining RNA (approximately 10 ng) was amplified in two
rounds with the RiboAmp RNA Amplification kit (Arcturus),
yielding between 30 and 60 mg of copy RNA. RNA from one
sample of very diffusely invaded white matter was also
isolated (after microscopic inspection) and amplified to
address the possible contribution of genetic material
admixed from normal brain surrounding the captured invad-
ing cells.
cDNA Microarray Analysis
Six micrograms of amplified RNA was labeled in a RT in
the presence of dUTP Cy3 (Amersham, Piscataway, NJ)
utilizing random hexamers as primers. Universal reference
RNA (Stratagene, La Jolla, CA) was amplified for one round
in the same manner and labeled with Cy5 dUTP (Amer-
sham). Labeled cDNA was hybridized overnight to 5750
gene cDNA microarray slides (Arizona Cancer Center, Tuc-
son, AZ). (The complete gene list can be found in Supple-
mentary Figure 1.) Following hybridization, slides were
washed, scanned, and quantitated with the Axon GenePix
4000 microarray reader (Axon Instruments, Foster City, CA).
Gene expression results were analyzed using GeneSpring
(Silicon Genetics, Redwood City, CA) software. The meas-
ured intensity of each gene was divided by its reference
channel (signal from the universal reference RNA) in each
sample. When the fluorescence intensity of the reference
channel was below 10, the data point was considered unin-
formative. Intensity-dependent normalization was also
Figure 1. QRT-PCR validation of gene candidates differentially expressed between invasive rim cells and tumor core cells in cDNA microarray analysis. Names of
transcripts analyzed are on the x-axis and the mean fold differential regulation (difference in relative copy number, where 1 represents equal expression in both
populations) is on the y-axis. Grey bars represent the mean gene expression levels of invasive tumor cells over tumor core cells seen in the cDNA microarray
analysis. Black bars represent the mean gene expression levels of invasive tumor cells over tumor core cells as evaluated by QRT-PCR using seven matched
tumor samples. White bars indicate the levels of gene expression (evaluated by QRT-PCR) in the diffusely invaded white matter from one of the samples used in
the cDNA microarray analysis divided by the expression levels from either invasive cells (left side, where candidates genes are upregulated) or tumor core cells
(right side, where candidate genes are downregulated) of the same sample. *Denotes genes with a significance of P V .05. **Denotes genes with a differential
expression that reaches a significance of P V .025 as calculated using the Wilcoxon signed-rank test.
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applied, where the ratio was reduced to the residual Lowess
fit of the intensity versus ratio curve. A fold change analysis
was performed to identify differentially expressed genes. The
ratios (sample over reference) for the three tumor core
experiments and four invasive rim experiments were aver-
aged and compared. Genes that were more than two-fold
upregulated or downregulated were selected. Next, to
address potential bias due to outliers, the gene lists were
further screened by verifying that the same rim/core trend
was present across samples that had matched core and rim
populations. Genes following the trend in two of the three
matched core/invasive rim sets were selected and tabulated.
Complete lists of differentially expressed genes can be found
in Supplementary Figure 2.
Quantitative RT-PCR (QRT-PCR) Validation
Total RNA was isolated from 500 to 1000 microdissected
tumor core and invasive rim cells from 11 additional tumor
samples as above. Seven samples were used to transcrip-
tionally validate each gene candidate. Tumor RNA and RNA
derived from the white matter adjacent to one of the tumor
samples were reverse-transcribed with oligo dT primers
using SuperScriptII (Invitrogen, Carlsbad, CA). The resulting
cDNA was amplified by PCR with gene-specific primers (the
list of primer sequences is available in online Supplementary
Figure 3) (Operon/Qiagen, Alameda, CA) using the Light-
Cycler and FastStart DNA Master SYBR Green I reagent
(Roche). Log-linearity of the amplification curve for each
primer set was confirmed down to the picogram range of
cDNA. Specificity of PCR products was confirmed by melting
curve analysis [14] and agarose gel electrophoresis. PCR
protocols are disclosed in online Supplementary Figure 3.
Quantification was done using Fit Points method of the
LightCycler software version 3.5 [14]. The cDNA amount
in each sample was normalized to the crossing point of the
housekeeping gene Histone 3B. Relative mRNA fold upre-
gulation in the invasive cells for each gene was calculated
using the respective crossing points applied in the following
Figure 2. Immunohistochemical analysis of six candidate genes ATX (C), BCLW (D), EFNB3 (E), PYK2 (F), IGFBP2 (G), and VIM (H); four overexpressed in the
invasive rim cells and validated by QRT-PCR; and two underexpressed in the rim, respectively. (A and B) H&E stains of the glioblastoma invasion front. (I)
Representative negative control. Large bold arrows point to the tumor core, and smaller arrows point at individually invasive glioblastoma cells. Original
magnification, 400, except (A) at 200.
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formula: F = 2(IHIG)(CHCG) (adapted from Ref. [15]),
where F = fold difference, C = core cells, I = invasive rim
cells, G = gene of interest, and H = housekeeping (Histone
3B). Statistical significance of the differential gene regulation
was assessed using the Wilcoxon signed-rank test.
Immunohistochemical Confirmation of Gene Candidates
The protein products of six gene candidates validated by
QRT-PCR were examined by immunohistochemistry on
three GBM specimens. Briefly, 6-mm sections were heated
for 2 hours at 65jC, deparaffinized in xylene and hydrated in
a graded alcohol series, and subjected to antigen-specific
epitope retrieval.
This was followed by quenching of endogenous perox-
idase activity through incubation in 3% hydrogen peroxide in
methanol. Slides were blocked with 10% normal serum in
0.1% Triton X-100 TBS and incubated overnight with the
respective antibody at 4jC. Secondary antibodies appropri-
ate to the primary antibody (Vectastain Kits; Vector Labo-
ratories, Burlingame, CA) were added for 1 hour at room
temperature, washed, and developed with DAB (Sigma,
St. Louis, MO). The slides were counterstained with hema-
toxylin 2 (Richard-Allen Scientific, Kalamazoo, MI) prior to
visualization. Antibody sources and epitope retrieval were
as follows: for ATX, slides were microwaved in 10 mM
sodium citrate, and antibody 100A (a generous gift from
Dr. Tim Clair) was used at a 1:500 dilution. Slides stained
for BCLW were digested for 30 minutes at 37jC in 0.5%
pepsin in 0.01 N HCl, using a 1:25 dilution BCLW N-19
(Santa Cruz Biotechnology, Santa Cruz, CA). Treatment for
EFNB3 included microwaving in 10 mM sodium citrate and
a 1:100 concentration of EFNB3 antibody (R&D Systems,
Minneapolis, MN). Slides for VIM were digested for
30 minutes at 37jC in 0.5% pepsin in 0.01 N HCl, fol-
lowed by a 1:200 dilution of VIM 3B4 (DakoCytomation,
Carpinteria, CA). Conditions for PYK2 pY402 (1:25;
Biosource, Camarillo, CA) were as previously described
[16], as were those for IGFBP2 sc-6001 (1:100; Santa Cruz
Biotechnology) [17].
Tissue Microarray (TMA) Assembly
A specific glioma invasion TMA was assembled by Dr. D.
H. Friedrich using patient-consented cases selected from a
database of histologic reports. Gliomas of WHO grades I to
IV (n = 69) and control cases (n = 25) including other tumors,
reactive gliosis, and ‘‘normal’’ brain specimens from epilepsy
surgery were included. Briefly, five equidistant microsamples
(600 mm cross section) were punched out of donor paraffin
blocks along a histologically verified invasion gradient and
arrayed into the TMA using an arraying device (Beecham
Instruments, Sun Prairie, WI) as described elsewhere [18].
The TMA paraffin block was then cut in 5-mm slices, which
were tape-transferred and subjected to the described stain-
ing methods.
Results
Microarray Analysis of Laser Capture–Microdissected
Glioma Cells Reveals Two Transcriptional Profiles
Using LCM, we collected two distinct GBM subpopula-
tions based on their pathologic and anatomic context. cDNA
gene expression profiling, followed by fold change analysis,
resulted in a list of differentially expressed genes that are
well documented in glioma biology. Among the genes
expressed in the tumor core whose expression is down-
regulated in invasive GBM cells were IGFBP-2 and IGFBP-5
(Table 1). Several transcriptional regulators involved
in growth control were expressed in the core, including
ZNF258, EYA2, EGR1, and JUNB. Genes whose products
are involved in signal transduction cascades such as PSHL,
PIM1, IQGAP, RDC1, and RGS16 were transcriptionally
depressed in invasive cells, as were the cytoskeleton-
related genes PFN1, MSN, PLEK, VIM, and CAPG. Angio-
genesis-related VCAM1 and VEGF, two genes well known
in glioma biology, reflect the high degree of neovasculariza-
tion of GBM. Heightened cellular proliferation, another
definitive characteristic of GBM, is represented by MCM2.
Interestingly, genes involved in drug resistance such as
Figure 3. Summary of immunohistochemical evaluation of ATX and BCLW in a glioma invasion tissue microarray. The tissue type examined and the number of
samples in each category are listed on the y-axis. The percentage of cases with positively staining cells within each category is on the x-axis. The shading scale
represents the percentage of positively stained cells within a sample. ATX TMA (A) evaluation showing a high degree of positive cells in gliomas of different grades,
but also in some neurons and reactive astrocytes. The TMA stained for BCLW (B) reveals its presence in gliomas of all grades.
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ABCC3 (multidrug resistance protein 3, MRP3 ) and metal-
lothioneins, which could play a role in intrinsic drug resist-
ance in gliomas, are highly expressed in tumor core samples
and downregulated in invasive cells. Finally, there was
evidence of a three-fold lower level of proapoptotic PIG3
(p53-induced gene 3) message in motile cells.
The transcriptome of invasive GBM cells illustrates their
biologic distinctivenes from their cognate tumor cores. Gene
candidates found to be upregulated two-fold or greater in
invasive cells suggests that they are functionally distinct cells
(Table 2). There was a preponderance of genes involved in
adhesion (OPCML and SPOCK), extracellular signal trans-
duction (PTPRN2, DKK3, EFNB3, GRIN2A, FGFR3, EGFR,
GPR19, and DTR), and cytoskeletal rearrangement (INA,
EMAP2, CHN1, and PYK2). The serine proteinase KLK6
was the only extracellular matrix–degrading enzyme differ-
entially expressed among the genes on the chip. We also
observed genes involved in intracellular signal transduction
(RGS7, EHD3, CS1, ITPK1, GRB2, and STK2), as well as a
subset of genes linked to apoptosis (CASP7, BCLW, and
DAP3). Some highly upregulated genes were difficult to
classify, such as ATX, an extracellular protein involved in
melanoma migration, and the intracellular calcium channel,
RYR2. In conclusion, it was possible to transcriptionally
differentiate cell populations from the same tumor that
resides in different microenvironments.
Table 2. Genes Upregulated in Invasive GBM Cells.
I/C Accession Number Name Description
Extracellular
7 AA436142 SPOCK Sparc/osteonectin, cwcv and
kasal-like domains
proteoglycan (testican)
6 AA425947 DKK3/RIG Dickkopf (Xenopus laevis)
homolog 3
6 AA115876 PI12 Serine (or cystein) proteinase
inhibitor, clade 1 (neuroserpin) 1
4 R76614 NTN14 Netrin4
Transmembrane proteins
69 H42679 HLA-DRA Major histocompatibility complex,
class II DM alpha
8 N62620 KCNK1 Potassium channel, subfamily K,
member 1 (TWIK-1)
7 R38201 OPCML Opioid-binding protein/cell
adhesion molecule-like
7 AA464590 PTPRN2 Protein tyrosine phosphatase
receptor type, N polypeptide 2
6 AA485795 EFNB3 Ephrin B3
6 H08933 GRIN2A Glutamate receptor, ionotropic,
N-methyl D-aspartate 2A
6 R40790 GABRG2 Gamma-aminobutyric acid
(GABA) A receptor, gamma 2
5 T80232 ATX Autotaxin (ectonucleotide
pyrophosphatase/
phosphodiesterase 2)
5 AA417654 FGFR3 Fibroblast growth factor
receptor 3
5 AA393408 PDE1A Phosphodiesterase 1A,
calmodulin-dependent
4 W48713 EGFR Epidermal growth factor receptor
4 AA454743 KLK6 Kallikrein 6
4 N94270 TPARL TPA-regulated locus
3 R17717 CDH13 Cadherin 13
3 H07878 GPRl9 G protein–coupled receptor 19
3 R14663 DTR Diphtheria toxin receptor
(heparin-binding EGF-like
growth factor)
3 AA479243 AMFR Autocrine motility factor receptor
Intracellular signaling
23 H23046 RGS7 Regulator of G-protein
signaling 7
15 R22326 EHD3 EH domain containing 3
11 R15791 RYR2 Ryanodine receptor 2 (cardiac)
10 AA064973 CS-1 Calcineurin-binding protein
calsarcin-1
6 R69354 SAC2 Sac domain containing inositol
phosphatase 2
4 AA464067 ITPK1 Inositol 1,3,4-triphosphate 5/6
kinase
3 AA449831 GRB2 Growth factor receptor–bound
protein 2
3 AA454947 AKAP1 A kinase (PRKA) anchor
protein 1
3 AA496013 STK2 Serine/threonine kinase 2
Cytoskeleton rearrangement
59 AA448015 INA Internexin, neuronal
intermediate filament
4 R27680 EMAP2 Microtubule-associated protein
like echinoderm EMAP
4 AA598668 CHN1 Chimerin (chimaerin) 1
3 H24688 SMARCC2 SWI/SNF– related, matrix-
associated, actin dep reg of
chromatin, C2
2 R85257 PYK2 Protein tyrosine kinase 2 beta
2 AA457036 P85SPR PAK-interacting exchange factor
beta (beta-pix)
Apoptosis
5 BCL2L2 Bcl2-like 2 (Bcl-w)
Table 2. (continued)
5 T50828 CASP7 Caspase 7, apoptosis-related
cysteine protease
3 R43325 DAP3 Death-associated protein 3
Transcription factors
9 AA459941 PEG3 Paternally expressed 3
5 H60572 TRABID TRAF-binding protein domain
4 N99243 TBX2 T-box 2
4 AA234897 MEF2C MADS box transcription enhancer
factor 2C
4 W00959 HLF Hepatic leukemia factor
3 R42479 ETS2 V-ets E26 oncogene
Unknown function
77 R67147 CRYM Crystallin mu
16 H54364 MAST3 Microtubule associated
serine/threonine kinase 3
11 H24428 KIAA0513 KIAA0513 gene product
8 AA452725 NUCB1 Nucleobindin 1
7 AA456008 AF1Q ALL1-fused gene from
chromosome 1q
7 W48780 NP25 Neuronal protein
6 W60581 BEX1 Brain expressed, X-linked 1
5 AA227594 MAL Mal, T-cell differentiation protein
4 H19439 DSCR1L1 Down syndrome critical region
gene 1– like 1
4 R59579 PGDS2 Prostaglandin D2 synthase
(21 kDa, brain)
4 H66616 GLG1 Golgi apparatus protein 1
3 H22481 NPTX1 Neuronal pentraxin I
3 H45376 NELL2 Nel (chicken)– like 2
3 T84156 LNX Multi-PDZ-domain–containing
protein
I/C = average cDNA microarray ratios of invasive cells over tumor core cells.
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Gene Candidate Validation by QRT-PCR
Gene candidates that discriminate invasive from tumor
core cells were validated by real-time QRT-PCR using
unamplified RNA (Figure 1). The genes chosen reflect
various cellular processes that may be involved in the biology
of the invasive phenotype, as well as some unknown, yet
highly differentially expressed candidate genes. Candidates
for validation were also chosen along the magnitude of the
range of differential gene expression to validate the selection
algorithm. Each gene’s differential expression was assayed
pairwise in corresponding tumor core and invasive rim from
seven different tumor samples. To address possible con-
tamination from surrounding normal brain tissues, RNA from
a section of white matter surrounding one of the tumors was
used to measure the expression of candidate genes in white
matter. We found that 15 of 17 of the gene candidates were
expressed 10-fold lower in the white matter compared to the
invasive tumor. The Wilcoxon signed-rank test was used to
analyze the statistical significance of the difference in gene
expression between the tumor core and the invasive cell
populations. Statistically significant changes in gene expres-
sion at the P V .025 level were seen with KIAA0513,
OPCML, EFNB3, BCLW, KLK6, CHN1, EMAP2, DAP3,
and PYK2 transcripts. Significant change in gene expression
at the .025 < P < .05 level was reached by an additional three
transcripts, EHD3, PTPRN2, and ATX. CASP7 was not
increased in six of seven tumor pairs examined, and thus
did not verify the cDNA microarray analysis. We also exam-
ined four gene candidates decreased in the invading GBM
cells. IGFBP2 and VIM transcript levels were greater than
two-fold lower in the majority of tumors analyzed (four of
seven and six of seven, respectively). IGFBP5 and MT1L
were only decreased in less than half of the seven tumors
analyzed. The directionality of the expression of these four
tumor core gene candidates did not reach statistical signifi-
cance using the Wilcoxon test. Differential transcription of
invasion gene candidates derived from microarray analysis
was validated by QRT-PCR and showed that the invasion
transcriptome was not significantly influenced by admixture
of genetic material from the white matter context in which
they were located.
Immunohistochemical Evaluation of Gene Candidates
Verification of protein product was undertaken in three
GBM samples for IGFBP2, VIM, ATX, EFNB3, BCLW, and
PYK2 (Figure 2). The invasion gene candidates ATX and
EFNB3 (Figure 2, C and E) are transmembrane proteins that
displayed predominantly cytoplasmic staining in the invading
cells, but also in the tumor core. BCLW was present in
invasive cells (Figure 2D), as well as in vascular endothelium
and, to a lesser degree, in reactive astrocytes (data not
shown). The biologically active, phosphorylated form of
PYK2 showed perinuclear localization in invasive glioma
cells as well as in some tumor core cells (Figure 2F). The
two candidates from the tumor core that were transcription-
ally downregulated in the infiltrating cell population were
visualized immunohistochemically in three GBM samples.
IGFBP2 (Figure 2G) showed distinct cytoplasmic staining in
the tumor core and somewhat lighter cytoplasmic staining in
invading cells. Cytoplasmic staining for IGFBP2 was also
visible, to a lesser extent, in astrocytes and reactive astro-
cytes present in the invaded white matter surrounding the
tumor. The intermediate filament VIM (Figure 2H) was
strongly present in the GBM tumor core, vascular endothe-
lium, astrocytes, and reactive astrocytes, but was markedly
reduced in invasive glioma cells. These data indicate that
the protein product of the selected genes is produced in
glioma cells.
TMA Analysis of ATX and BCLW
We further examined ATX and BCLW expression on an
invasion TMA assembled to reflect the dispersion of infiltra-
tive glioma of various grades and cellular origins (Figure 3).
ATX is strongly expressed in glioblastoma cells and is also
clearly expressed by WHO grade II and grade III gliomas.
Interestingly, it is highly expressed in the four pilocytic
astrocytomas (WHO grade I) examined. Positive staining is
evident in normal vascular endothelium and, to a lesser
extent, in tumor vasculature. Weaker expression is observed
in reactive astrocytes and Nissl bodies of some neurons. It is
weakly or not expressed by carcinoma metastasis and not
expressed by normal astrocytes and oligodendrocytes
(Figure 3A). Further analysis of 10 GBM cases revealed that
of the invasive cells, 51% were ATX-positive, whereas only
30% of tumor core cells had ATX immunopositivity (data not
shown). One such representative tumor is illustrated in
Supplementary Figure 4. BCLW immunopositivity is weaker,
but it is nonetheless detectable in glioma cells. Its expression
mildly increases, with progressive malignancy grades reach-
ing its peak in GBM (Figure 3B). As with ATX, no expression
was seen in normal astrocytes and oligodendrocytes, nor
was it present in metastatic adenocarcinoma or medulloblas-
toma. These data show that ATX and BCLW, two proteins
not previously associated with glioma biology, are expressed
in invasive glioma cells.
Discussion
Glioblastomas display a notoriously heterogeneous pheno-
typic presentation [19], yet there are key genetic changes
that define these tumors [20]. Epidermal growth factor
receptor (EGFR) overexpression/amplification occurs in pri-
mary GBM, which constitutes roughly 50% of gliomas. GBM
that progresses from lower grades (secondary GBM) does
not overexpress EGFR, but exhibits a loss of p53 [21].
These molecular subtypes of glioblastoma have distinct
transcriptional profiles [22], which will be useful in targeting
new therapies to a potentially more responsive subset of
tumors. Previous gene expression profiles of glial tumors
show that GBM can be differentiated from lower grades of
astrocytic tumors through a characteristic group of upregu-
lated genes [6]. Our studies reflect the expression of such
GBM hallmark genes, which include IGFBP2, IGFBP5,
VEGF, VCAM1, EGFR, MCM2, and TNC [4–6] in both tu-
mor core and invasive cells. Interestingly, most of these
genes are downregulated in the invasive cell population
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relative to the tumor core. Expression of these genes in
conjunction with the histopathologic diagnosis confirms the
identity of the infiltrating cells as GBM cells. Analysis of the
gene expression profile from the white matter surrounding
one of the tumors indicates that the gene expression profile
of invasive glioma cells is not attributable to contaminating
mRNA from the white matter that they invade (Figure 1).
Furthermore, glial fibrillary acidic protein (GFAP) is moder-
ately transcriptionally downregulated in invasive glioma cells
as compared to the tumor core population (Table 1). Immu-
nohistochemical staining for GFAP further corroborates
this finding (Supplemental Figure 5) and reveals that GFAP
levels are much higher in normal and reactive astrocytes
than in invasive tumor cells. Because GFAP levels are re-
duced with increasing astrocytic malignancy [23], it follows
that the invasive transcriptome is not influenced by contribu-
tion of genetic material stemming from reactive astrocytes.
The importance of the tumor’s microenvironment as a
contributing factor to gene expression changes should not be
overlooked [24]. Cells at the tumor core are densely packed,
proliferative, and may experience considerable hypoxia lead-
ing to extensive areas of necrosis. Individually infiltrating
cells interact with the extracellular matrix and diverse cells
residing in the brain parenchyma, incorporating signals as
they invade. Interactions with such diverse microenviron-
ments likely contribute significantly to the initiation and
maintenance of these discrete transcription profiles.
The expression profile of invasive glioma provides new
insight into the interplay of the concerted molecular phenom-
ena activated during invasion. Two such apparently linked
mechanisms are motility and apoptosis resistance. Various
types of cancer, such as glioma [11,25], gastric cancer [26],
Kaposi’s sarcoma [27], and pancreatic cancer [28], show
evidence for this relationship. Recent evidence suggests that
this occurs at the level of gene expression in breast cancer
[29] and glioma [30], corroborating our findings that the
invasion transcriptome shows a concomitant upregulation
of genes involved in motility and apoptosis resistance.
Genes Involved in Motility-Related Pathways Are
Differentially Regulated in Invasive Cells
Motility is dependent on cytoskeletal rearrangement and
the extension of filopodia and then lamellipodia at the leading
edge; these phenomena are modulated by Cdc42, Rac, and
Rho [31]. The tight regulation of actin polymerization also
emerges from this molecular portrait. Heightened expression
of capping protein and profilin in the tumor core may inhibit
filamentous actin polymerization and elongation, as over-
expression of profilin in breast cancer reduces migration and
invasion [32]. ERM (ezrin, radixin, and moesin) proteins, two
of which are overexpressed in the core, act as linkers
between the plasma membrane and the actin cytoskeleton,
impairing migration-associated processes, such as cell
spreading, attachment, and motility [33,34]. Involvement of
small G-protein signaling and motility-related cytoskeleton
rearrangement are illustrated by the differential expression of
chimaerin alpha 1 (CHN1), a GTPase-activating protein
for Cdc42 and Rac1 [35], which induces the formation of
lamellipodia and filopodia in neuroblastoma cells [36]—key
hallmarks of Cdc42 and Rac1 activation. Microinjection of
full-length CHN1 colocalizes with filamentous actin micro-
spikes as well as with membrane ruffles, and is involved in
the redistribution of focal adhesion protein vinculin. PYK2 is a
member of the focal adhesion kinase family of nonreceptor
tyrosine kinases; it is closely involved with src-induced
increased actin polymerization at the fibroblastic cell periph-
ery [37]. Its role in glioma migration/invasion is becoming
clearer, as overexpression of PYK2 induced glioblastoma
cell migration in culture [16]. Levels of activated PYK2
positively correlated with the migration phenotype in four
glioblastoma cell lines (SF767, G112, T98G, and U118)
tested in a two-dimensional migration assay [16]. Our anal-
ysis of activated PYK2 in GBM invasion in situ revealed
strong staining in infiltrating GBM cells.
Tumor mitogens such as the cytokine ATX, which is an
autocrine motility factor in melanoma [38] and breast cancer
[39], as well as an autocrine motility factor receptor [40] and
Netrin 4 [41], are also involved in promoting cell movement.
A growing body of literature documents ATX’s role in cancer
invasion; we therefore chose to examine its expression in a
glioma invasion–specific TMA. Evaluation of ATX staining
revealed that it is expressed in all grades of glioma, but not in
normal astrocytes. It also appears that almost twice the
number of invasive tumor cells expresses ATX when com-
pared to its expression in the tumor core. These findings
suggest that the role of ATX in glioma invasion should be
examined further.
Invasive Cells May Pre-empt Apoptosis
There is a positive correlation between apoptosis index
(AI) and progressive grades of astrocytoma malignancy
[42,43]. However, within GBM, there is a direct correlation
between AI and patient survival, indicating that the most
malignant GBM (measured by a shorter progression-free
survival) has a lower rate of apoptosis [44]. It is of interest
that the most malignant tumors are highly invasive [45].
Higher expression of antiapoptotic bcl-2 family proteins in
recurrent GBM, even in patients who did not receive adjuvant
chemotherapy or radiotherapy, points to the intrinsic resist-
ance to apoptosis of these tumors [46]. We report BCLW (a
member of this family), which is transcriptionally upregulated
and expressed in invasive glioma cells. This finding reflects
the previously observed expression of BCLW in infiltrative
morphotypes of gastric cancer [47]. The mechanism by
which BCLW acts in glioma cells is not known, but this family
of apoptosis suppressors has been implicated in coordinat-
ing Ca2+ balance between the endoplasmic reticulum (ER)
and mitochondria [48]. Recently, Ca2+ homeostasis has
been linked to apoptosis [49], showing that Ca2+ release
from the ER protects cells from apoptosis; interestingly, Ca2+
release is modulated, in part, by ryanodine receptors [50]
and we found RYR2 to be consistently upregulated in
invasive glioma cells.
A direct correlation between invasion and apoptosis
resistance can also be effected by modulation of apoptotic
signaling. Such may be the case with DAP3, originally
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described as a proapoptotic protein that transduces tumor
necrosis factor ligand–dependent signals from death recep-
tor DR4 through FADD (Fas-associated by death domain)
[51] in fibrosarcoma cells. DAP3, however, was also
described as an antiapoptotic factor in migrating glioma
cells [11]. We propose that the equilibrium between proa-
poptotic and antiapoptotic proteins may be regulated, in
part, by transcriptional activation of apoptosis modulators
(such as DAP3) and antiapoptotic genes (such as BCLW)
during activation of the invasive phenotype.
Current treatment for GBM includes surgical resection,
chemotherapy, and radiotherapy, but despite continuous
improvements in these approaches, patients’ median sur-
vival remains at 1 year. New treatment modalities such as
targeted therapy with monoclonal antibodies and immuno-
toxin-conjugated antibodies [52] are aimed at tyrosine kinase
receptors such as EGFR and PDGFR, which are frequently
overexpressed in glioblastomas. Gene therapy for GBM
has met with some success in clinical trial [53], but is still in
the early stages of development. Signaling pathways such
as those involving EGFR, PDGFR, PI3K/AKT, and RAS can
be targeted with small molecule inhibitors. However, most
of these approaches predominantly address key pathways
involved in cell proliferation, whereas recurrent tumors
regrow from the cells that have invaded the brain and may
be temporally less proliferative [54]. This preliminary study
of glioma invasion–related gene regulation suggests targets
that are potentially upregulated in gliomas regardless of
their molecular etiology. Further transcriptional profiling of
invasive GBM cells in more tumors with known EGFR and
p53 status should clarify if this profile can be subcategorized
according to current molecular classifications. An expanded
approach including transcriptional profiling of diffusely infil-
trating gliomas of lower grades may lead to insight into
general biochemical mechanisms necessary for invasion.
In conclusion, we propose that the gene expression
profile of invading glioma reveals a pattern unique to this
discrete population of cells. These transcriptional differences
point to reasons why invasive GBM cells are unlikely to
respond to conventional therapies aimed at a proliferative
and stationary tumor mass that has been the reference
tissue for the molecular genetic analysis of this disease.
Understanding the genetic basis of the invasive behavior
may lead to novel combination therapies that not only
address the tumor core, but also this distinct subpopulation
of cells that have proven refractory to treatment. We antici-
pate that this will suggest novel intervention strategies
through combined modification of apoptotic cascades, or
potential use of small compounds targeting extracellular
receptors expressed by invading glioma cells.
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